AllSci News
Sparian Biosciences advances non-opioid pain drug toward clinical testing with NIDA support
Sparian Biosciences, a New York-based for-profit company, has received a USD 3.1 million NIDA UG3 grant to advance SBS-147, an oral non-opioid analgesic,...
JCVI receives USD 1.79 million NIAID grant to advance phage therapy toward FDA IND
J. Craig Venter Institute has received a USD 1.79 million NIAID R01 award to advance a five-phage therapeutic cocktail targeting antibiotic-resistant...
Cūrza backed by NIAID award for novel ribosomal inhibitor to combat multidrug-resistant infections
Curza Inc, a Salt Lake City-based antibiotic developer, has received a USD 1 million NIAID SBIR award to advance CZ-02, a novel class of oral antibiotics...
Sanford Burnham Prebys develops single-construct gene therapy to boost cardiac cell reprogramming in heart failure
Sanford Burnham Prebys Medical Discovery Institute, the La Jolla, California-based nonprofit research institute, has received a USD 1.6 million NIH R01...
Talus Bio backed by NCATS for AI platform to unlock transcription factors as drug targets
Talus Bioscience Inc, a Seattle-based drug discovery company, has received a USD 1.03 million SBIR R44 grant from the National Center for Advancing...
Teva secures ocrelizumab biosimilar rights across US and EU ahead of subcutaneous shift
Teva and Polpharma Biologics strike ocrelizumab biosimilar deal covering US, EU, and key global markets
Forte's becomes first to beat placebo in vitiligo with durable post-treatment gains
Dallas-based Forte Biosciences, Inc. (Nasdaq: FBRX) has reported statistically significant repigmentation data from a Phase Ib double-blind,...
Alchemab backed by British Business Bank with record USD 34 million life sciences bet
UK-based Alchemab Therapeutics has announced a £25 million (USD 34 million) extension to its Series A financing, with the capital provided solely by the...
Novo Nordisk agrees to evaluate Vivani's semaglutide implant ahead of Phase I trial
Novo Nordisk agrees to evaluate Vivani's semaglutide implant ahead of Phase I trial
GSK terminates USD 2.2 billion Alector collaboration after back-to-back clinical failures in dementia
GSK terminates Alector collaboration after back-to-back clinical failures in progranulin biology, ending a deal worth up to USD 2.2 billion and leaving the...
Tanabe Pharma exits manufacturing with plant sale to reshape as pure R&D player
Japan-based Towa Pharmaceutical Co., Ltd. (TSE: 4553) has agreed to acquire Tanabe Pharma Factory Co., Ltd., the manufacturing subsidiary of Tanabe Pharma...
Ipsen's Dysport becomes first botulinum toxin to beat placebo in episodic migraine Phase III trial
France-based Ipsen (Euronext: IPN; ADR: IPSEY) reported that abobotulinumtoxinA (Dysport) met primary endpoints in both the E-BEOND and C-BEOND Phase III...
Prime Medicine prevails in Beam dispute, retaining exclusive rights to AATD therapy PM647
An arbitration tribunal has confirmed that Massachusetts-based Prime Medicine (Nasdaq: PRME) holds exclusive development rights over PM647, its investigational prime editing therapy…
FDA expands Octapharma’s Wilate into pediatric von Willebrand disease prophylaxis
The US FDA issued an approval to expand the label of Wilate (von Willebrand Factor/Coagulation Factor VIII Complex [Human]) for routine prophylaxis…
Wugen rebrands as Allotera, raises USD 150m for off-the-shelf CAR-T push
St. Louis-based Allotera Therapeutics, Inc. (formerly Wugen, Inc.) has closed a USD 35 million financing round comprising equity and venture debt, bringing...
The AllSci Brief
Free, systematic R&D and deal news. Daily.